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Background: Health-related quality of life (HRQoL) values shortly after pacemaker (PM) implantation for brady-
cardia have been established, however little is known about long-term HRQoL.
Methods: Using the generic SF-36 and the PM speciﬁc Aquarel questionnaire, HRQoL was repeatedly measured
during a 7.5 year follow-up period in 881 bradycardia PM recipients included in the large scale nationwide
Dutch FOLLOWPACE study. HRQoL over time, corrected for age, gender, diabetes, hypertension, heart failure,
cardiovascular disease and AV-synchrony, was assessed with a linear mixed model.
Results: Increased scores both on overall SF-36 and on all SF-36 subscales were observed shortly after implanta-
tion. Although scores on SF-36 gradually declined over time, scores remained improved over the measured
pre-implantation values. Also, scores for almost all subscales remained increased throughout the 7.5 year obser-
vation period, except for physical functioning which showed a gradual decline several years after the initial rise.
Additionally, higher scores on all Aquarel scales were observed after implantation. Scores on the arrhythmias and
chest discomfort subscales improved and remained stable throughout follow-up (FU), whereas the dyspnea at
exertion subscale showed a gradual decline during FU to reach pre-implantation values at 5 years.
Conclusions: Increased HRQoL is observed not only shortly after PM implantation, but also after long-term FU.
Clinical Trial Registration: ClinicalTrials.gov Identiﬁer: NCT00135174; http://www.clinicaltrials.gov/ct2/show/
NCT00135174.© 2013 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Health-related quality of life (HRQoL) represents the individual
patient's well-being and functioning in daily life and has become a
valuable resource in the recognition of the impact of therapeutic
measures on patients' health [1]. Several studies have reported
about HRQoL after pacemaker (PM) implantation for conventional
reasons [13], showing a clear improvement in HRQoL values mea-
sured at several months [2–6] or 1 year after implantation [7,8].nent Scale; MCS, Mental Com-
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Ltd. All rights reserved.However, PM implantation does not constitute a single interven-
tion, but rather an ongoing treatment with successive device checks,
and if required adjustments in pacing settings and repeated surgery
for device replacement. PM therapy has an enduring impact on the
recipient's life and therefore the assessment of long-term HRQoL
after PM implantation matters even more than measurements shortly
after implantation. Very few studies, however, report on long-term
HRQoL in PM recipients [9].
The nationwide FOLLOWPACE study started in 2003 in the
Netherlands, and was designed to evaluate short and long term out-
comes in a contemporary, unselected prospective cohort of patients re-
ceiving a ﬁrst PM for conventional bradycardia indications [13]. The aim
of the present analysis was to measure the HRQoL during long-term
follow-up. These ﬁndings can be applied to inform, counsel and reassure
patients that undergo a PM implantation.
2. Methods
2.1. Patients
Patients for this HRQoL-substudy were recruited from the FOLLOWPACE study, a
prospective nationwide, multicenter cohort study conducted in 23 PM centers in the
Netherlands. The design of the FOLLOWPACE study has been published previously
[10–12]. In brief, consecutive patients aged 18 years or older, who received a ﬁrst
Table 1
Baseline characteristics of the 881 patients with multiple measurements of health re-
lated quality-of-life (HRQoL).
n %
Male 516 58.6
Agea 72.2 (10.7)
Body mass indexa 26.4 (3.6)
History
Atrial tachy-arrhythmias 330 37.5
Cardiac surgery (CABG or valve surgery) 151 17.1
Coronary artery disease 168 19.1
Cardiac valve disease 178 20.2
Congestive heart failure 92 10.4
Prior cerebrovascular accident 80 9.1
Diabetes 125 14.2
Hypertension 537 61.0
Use of anticoagulant drugs (ASA or coumarins) 524 59.5
Use of antiarrhythmic drugs 145 16.5
Main indication for implantation
Atrio-ventricular conduction disturbances 364 41.3
Sick sinus syndrome, brady-tachycardias 304 34.5
Atrial ﬁbrillation with slow ventricular response 161 18.3
Other 52 5.9
Implantation and PM related characteristics
Vena subclavia used for venous access 803 91.1
Vena cephalica used for venous access 78 8.9
Single chamber system AAI(R) 15 1.7
Single chamber system VVI(R) 197 22.4
Dual chamber system 669 75.9
Passive atrial lead ﬁxation 193 21.9
Passive ventricular lead ﬁxation 627 71.2
Pacing mode at discharge
Dual 637 72.3
Ventricular 205 23.3
Atrial 39 4.4
Data are presented as counts with percentages unless otherwise speciﬁed.
CABG: coronary artery bypass grafting; ASA: acetylsalicylic acid.
a Mean with SD.
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eligible if they were taking any investigational drug or had a non-approved or investi-
gational PM implanted. In addition, patients with diseases at implant that were likely
to cause death or severe morbidity during the 1st year after implantation such as active
cancer were excluded. All patients provided written informed consent before PM im-
plantation, and were asked to conﬁrm their consent regarding the HRQoL-substudy
2 years after implantation. This study complies with the Declaration of Helsinki and
the protocol for this study was approved by the Ethical Commission of the University
Medical Center Utrecht. The authors of this manuscript have certiﬁed that they comply
with the Principles of Ethical Publishing in the International Journal of Cardiology.
Inclusion took place from January 2003 till November 2007. Follow-up lasted until 1
November 2010.
2.2. Health related quality of life (HRQoL)
HRQoL was measured before PM implantation, and several times during follow-up,
using the generic SF-36 questionnaire (Medical Outcomes Study Short-Form Health
Survey) [14,15] and the validated Aquarel questionnaire [6,16], that was speciﬁcally
developed for PM patients. Questionnaires were sent by postal service to all partici-
pants, and a reminder-letter with an additional copy of the questionnaire was sent in
case the questionnaire was not returned within 6 weeks. All received questionnaires
were classiﬁed around 6 month timeframes after PM implantation.
2.3. SF-36
The validated Dutch version of the SF-36 questionnaire was used to assess HRQoL
[15,17]. It incorporates two composite scales – the Physical Component Scale (PCS) and
the Mental Component Scale (MCS) [18] – derived from eight domains: physical func-
tioning (PF), role limitations due to physical health problems (RP), bodily pain (BP),
general health perceptions (GH), vitality (VT), social functioning (SF), role limitations
due to emotional problems (RE) and general mental health (MH). All scores are scaled
from 0 to 100, with lower scores representing a lower HRQoL.
2.4. Aquarel
The Aquarel (Assessment of QUality of life And RELated events) questionnaire was
developed as a disease speciﬁc extension to the SF-36, for patients with cardiac rhythm
disorders requiring chronic pacing. It consists of 23 additional questions related to car-
diac complaints or rhythm disorders. The results of these questions can be summarized
into three subscales: chest discomfort, dyspnea at exertion, and arrhythmias, each
scaled from 0 to 100, with lower scores representing a lower HRQoL. The Aquarel is
translated and validated in several languages [19,20].
2.5. Data analysis
We analyzed the HRQoL values during the entire follow-up using a linear mixed
model [21]. An important advantage of these models is their robustness for dealing with
missing follow-up measurements and different numbers of follow-up measurement
across patients [21]. Further, to account for dependency across the repeated HRQoL mea-
surementswithin the samepatientswe included an autoregressive residual (i.e. GEE type)
covariancematrix [22,23], and a random intercept for individual differences in HRQoL be-
tweenpatients. AsmostHRQoL scales showed a skeweddistribution,we used robust stan-
dard errors to estimate conﬁdence intervals and to perform Wald tests [24]. The HRQoL
values over timewere corrected for the inﬂuences of gender, age, the presence of diabetes,
hypertension, congestive heart failure, retainedAV-synchrony (AAI/DDD opposed to VVI),
and a history of cardiovascular disease (i.e. cardiac surgery, cardiac valve disease, coronary
artery disease and prior stroke).
Additionally, we examined the determinants for long term HRQoL using the same
linearmixedmodel. Statistical analyseswere performed using SPSS forWindows (version
17; SPSS, Chicago, IL, USA) and SAS (version 9.2, SAS Institute Inc., Cary, NC, USA).
3. Results
1067 (70%) patients provided informed consent for the HRQoL
substudy, at time of implantation. Of these, 16 patientswithdrew their in-
formed consent and 76 patients died before completing a second HRQoL
questionnaire. Seven patients were incapable of returning a second
HRQoL questionnaire due to dementia, 3 patients were lost-to-FU, and
84 patients did not respond to repeated reminders.
This resulted in 881 (82%) patients having at least 2 HRQoLmeasure-
ments during follow-up that could be included in the analysis. Mean age
at time of ﬁrst implant was 72 years (SD 10.7) and therewere 516 (59%)
males (Table 1). Main indication for PM implantation was atrioventricu-
lar conduction disturbances in 364 (41%), sick sinus syndrome (SSS) or
bradyarrhythmias in 304 (35%), and atrial ﬁbrillation with slow ventric-
ular response in 161 (18%), and a PMwas implanted in 52 patients (6%)for other indications (e.g. hypersensitive carotid sinus syndrome). Most
implanted PM systems were dual chamber devices (76%).
A total of 3221 HRQoL questionnaires were received during the
7.5 year observation period between ﬁrst implantation in 2003 and
the end of follow-up in November 2010. During follow-up, after the
completion of a second HRQoL questionnaire, 175 (20%) patients died,
and 20 (2%) patients at some point withdrew their informed consent,
mostly reporting to be unable to ﬁll out subsequent questionnaires
because of age related problems, e.g. dementia or visual impairment.
72 (8%) patients did not respond to repeated reminders.
3.1. SF-36
The overall SF-36 and the MCS and PCS improved after PM implan-
tation (Fig. 1, panel A). The largest increase in HRQoL was observed in
the overall SF-36, and although scores gradually declined over time,
values remained improved compared to pre-implantation values
throughout our 7.5 year observation period. Scores on the MCS were
improved as well, and scores remained stable during subsequent
follow-up. Scores on the PCS however, only showed improved values
during the ﬁrst 2 years after implantation, followed by a slow decline
to scores comparable to pre-implantation values thereafter.
3.2. SF-36 subscales
Higher values for all SF-36 subscales were observed one year after
implantation compared to pre-implantation values, with the exception
of GH scores (Fig. 1, panels B and C). Observed values for GH throughout
the ﬁrst 4 years were comparable to pre-implantation values, whereas
slightly lower scores were observed thereafter. Similarly, observed
scores for the PF scale were higher during the 1st year after
Fig. 1. Estimated health related quality-of-life (HRQoL) during long-term follow-up after ﬁrst bradycardia pacemaker implantation, corrected for age, gender, diabetes, hypertension,
heart failure, maintained AV-synchrony, and cardiovascular disease.
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comparable to pre-implantation values during the 2nd and 3rd year,
and lower scores after 3 years.
The RP, RE, SF and MH scales showed higher scores throughout the
7.5 year observation period. Scores for both BP, as well as VT showed
a gradual decline after the initial rise. Despite in time lowering scores,
observed scores for VT were higher compared to pre-implantation
values for theﬁrst 6 years after implantation. For BP, scoreswere higher
during the 1st, 2nd and 3rd year after implantation and comparable to
pre-implantation values during subsequent years.
3.3. Aquarel
The PM speciﬁc HRQoL-Aquarel values showed an increase in all
scales in the ﬁrst year after implantation (Fig. 1, panel D). Themost pro-
nounced effect was observed on the arrhythmias subscale. During
long-term follow-up this increase in HRQoL score was maintained.
The chest discomfort subscale showed similar observations, with an
increase in HRQoL scores shortly after implantation that remained
stable during subsequent years. An increase in score on the dyspnea at
exertion subscale was observed shortly after implantation, followed
by a gradual decline over the following years to reach values compara-
ble to pre-implantation score in the 5th year after implantation.
3.4. Determinants of HRQoL
Age at time of implantation, female gender, diabetes, hypertension
and a history of congestive heart failure signiﬁcantly contributed to a
worse overall HRQoL asmeasuredwith SF-36 (Table 2). On the different
Aquarel subscales, however, these determinants showed varied effects
(Table 2). The presence of cardiovascular disease was associated with
a worse HRQoL on both SF-36 and Aquarel, whereas no difference was
observed between patientswith VVI or AAI/DDDon either HRQoL-scale.
4. Discussion
This large cohort study on long-term HRQoL in bradycardia PM
recipients observed an increase in all measured HRQoL subscales in
the ﬁrst year after PM implantation. Moreover, an increase in HRQoL
scores compared to pre-implantation values was observed for most
subscales during our 7.5 year follow-up period.
Although the increase in HRQoL values is maintained during our
7.5 year follow-up period, a different course for separate subscales is
clear. Notably, overall SF-36 and mental scores were higher compared
to pre-implantation values throughout the observation period, whereas
the physical scoreswere only increased in the ﬁrst 2 years after implan-
tation and declined thereafter (Fig. 1, panel A). Moreover, scores on the
general health subscale only showed a moderate increase after implan-
tation, followed by a gradual decline over time. Also, scores for bodily
pain were comparable to pre-implantation values after the 3rd year.Table 2
Regression coefﬁcients (with 95% conﬁdence intervals) for determinants of long term
questionnaire.
SF-36 Aquarel
Overall SF-36 Chest discomf
β (95% CI) p-Value β (95% CI)
Female gender −6.1 (−8.3–−3.9) b .0001 −1.6 (−2.9–−
Age (per 10 years increase) −4.0 (−5.0–−3.0) b .0001 0.0 (−1.0–0.0
Diabetes −4.9 (−7.8–−1.9) 0.0014 −0.9 (−2.6–0
Hypertension −2.8 (−5.2–−0.4) 0.0212 −1.5 (−2.8–−
Heart failure −3.8 (−7.5–−0.1) 0.0459 −0.4 (−2.3–1
Cardiovascular disease −3.4 (−5.7–−1.2) 0.0032 −2.1 (−3.3–−
Maintained AV-synchrony (AAI/DDD) 0.6 (−2.2–3.4) 0.6860 −0.1 (−1.5–1This gradual decline in scores for physical domains will likely be the
effect of non-cardiovascular comorbid diseases, as often extensively
present in this elderly patient population. However, the role limitations
due to emotional problems, the role limitations due to physical health
problems, and the social functioning subscales, that all measure prob-
lemswithwork or other daily activities as a result of the studied disease,
showed persistent increases after PM implantation reﬂecting improved
well-being.
Previous studies of HRQoL in pacemaker recipients addressed the
improvement in HRQoL observed shortly after pacemaker implantation.
Although many of these studies looked at speciﬁc patient populations
[8,25] or assessed HRQoL changes as a result of different pacing
modes [5,9,25–27], or sensor settings [28,29], our results are in agree-
ment with these previous studies. Our results extend these previous
observations with long-term HRQoL data after PM implantation.
The only long-term HRQoL measurements in bradycardia PM recipi-
ents were reported from the MOST-trial [9,30], in which 2010 patients
with sick sinus syndrome were randomized to dual chamber pacing or
ventricular pacing, and observed for a median of 33 months. HRQoL
was increased 3 months after PM implantation for all SF-36-subscales.
At 4 year follow-up scores for the role functioning and mental health
subscales were still above pre-implantation values, whereas scores for
the physical domains were comparable to pre-implantation values or
less. This pattern and themagnitude of changes are similar to our results.
4.1. Determinants of HRQoL
Our study found lower long term HRQoL on the overall SF-36 in
women compared to men, and worse long term HRQoL at higher age.
Both ﬁndings are consistent with previous literature. For instance,
Fleischman et al. observed less improvement in functional status and
physical scores among subjects≥75 years [9]. Also, on Aquarel subscales
women hadworseHRQoL thanmen,whereas higher agewas of no inﬂu-
ence on long term HRQoL measures [19]. Additionally, long term worse
HRQoL was observed in patients with known cardiovascular disease,
indicating the association between co-morbidity and long term HRQoL
measures as discussed above.
We observed no clear association betweenmaintained AV-synchrony
(AAI/DDD) and HRQoL. Initially small, cross-over studies reported better
HRQoL when patients had DDD pacing compared to VVI pacing mode
[25,31], however more detailed analysis from data of large clinical trials
as MOST, CTOPP and PASE, showed no difference in HRQoL between
pacing modes [5,32,33]. In addition, other observational studies found
no difference in HRQoL between pacing modes [19,20,34].
4.2. Strengths and limitations
To the best of our knowledge, this is the largest prospective obser-
vational study in patients receiving bradycardia pacing therapy,
conducted in a nationwide population among 23 Dutch hospitals.
Patients were unselected with regard to pacing indication and typeHRQoL values, measured with overall SF-36 and the pacemaker speciﬁc Aquarel
ort subscale Dyspnea subscale Arrhythmia subscale
p-Value β (95% CI) p-Value β (95% CI) p-Value
0.4) 0.0078 −2.6 (−3.8–−1.4) b .0001 −7.1 (−9.1–−5.1) b .0001
) 0.5773 −1.0 (−2.0–−1.0) b .0001 1.0 (0.0–1.0) 0.2644
.9) 0.3488 −2.0 (−3.7–−0.4) 0.0170 −2.9 (−6.0–0.2) 0.0639
0.3) 0.0162 −2.2 (−3.4–−0.9) 0.0008 −3.3 (−5.4–−1.2) 0.0022
.5) 0.6829 −2.6 (−4.7–−0.5) 0.0162 1.7 (−1.3–4.8) 0.2653
0.9) 0.0006 −2.1 (−3.3–−0.9) 0.0010 −3.1 (−5.1–−1.0) 0.0029
.4) 0.9443 0.6 (−0.8–2.0) 0.3955 1.7 (−0.8–4.1) 0.1776
2163E.O. Udo et al. / International Journal of Cardiology 168 (2013) 2159–2163of pacemaker. Our results therefore reﬂect current clinical practice,
making them highly generalizable to other populations.
Most longitudinal HRQoL studies were analyzed with repeated-
measurement analysis of variance, where one missing questionnaire
will result in omitting all data of that particular patient. Analysis by
mixed-effects models, as performed in our study, has the advantage that
all availablemeasurements could be included in the analysis. Additionally,
bias due to missing measurements and unmeasured co-morbidities was
reduced with the inclusion of covariates and a random intercept in the
analysis [21].
Some limitations, however, have to be acknowledged. First, although
we accounted for cardiovascular co-morbidities, information on mental
well-being (i.e. depression) and other co-morbidities, such as malignan-
cies or pulmonary disease, were not recorded and could not be included
in the analysis. As a result, some bias may have been introduced, as
loss-to-follow-up may very well be related to co-morbidity. Higher
HRQoL scores would likely have been observed in case corrections for
these co-morbidities could be applied. Second, observations were
clustered in 6 month time-frames to provide for a comprehensive, easy
to interpret overview of HRQoL over time. This may have introduced
some bias, even though HRQoL scales like the SF-36 remain stable over
short periods of time [17,35].
Furthermore, although tempting given the robust analyses and
adjustment for covariates, the present analysis does not allow for infer-
ences on the effectiveness of pacemaker implantation on improved long
term HRQoL, simply due to the absence of a control group. An increase
in HRQoL after PM implantation has been described due to the placebo
effect [36]. Although this effect is believed to wane over time [37], a
placebo-effect can therefore never be fully excluded, even in our long
term study. However, the persistence of the observed increase in
HRQoL in our view strongly suggests effects beyond the placebo-
effect. Of course, at present a randomized trial on this matter would
not be considered ethical.
5. Conclusion
HRQoL measurement with SF-36 and the PM speciﬁc Aquarel ques-
tionnaire showed an increase in HRQoL shortly after PM implantation.
During long-term follow-up scores on the overall SF-36 gradually de-
clined. However, the increased scores on the role functioning andmental
health subscales, as well as on the arrhythmia and chest discomfort
scales of the PM speciﬁc Aquarel questionnaire, were retained during
long-term follow-up.
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